{
    "id": 13374,
    "fullName": "ABL1 G250E",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 G250E lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250E has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040), results in increased catalytic efficiency (kcat/km) in an in vitro assay (PMID: 30684523), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown.",
            "references": [
                {
                    "id": 14163,
                    "pubMedId": 30684523,
                    "title": "The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30684523"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "G250E",
    "createDate": "10/29/2015",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 119173,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862962G>A",
        "cDna": "c.749G>A",
        "protein": "p.G250E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18897,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18918,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20122,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20138,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6251,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 67% (8/12) of chronic myeloid leukemia patients harboring ABL1 G250E in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 G250E in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20995,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 G250E in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7987,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a complete cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 G250E (27%) and G250E/E279V (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23161,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 E279V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7982,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 Y253H (94%), and G250E/F317L (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26126,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 Y253H ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7992,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359I (84%), F359I/T277I (2%), G250E (1%), and E507G (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26130,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 G250E and T315I in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 G250E and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 G250E and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20982,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and G250E in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35473,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 G250E and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35477,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13560,
            "profileName": "ABL1 G250E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22838,
            "profileName": "BCR - ABL1 ABL1 G250E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23153,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23161,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 E279V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26126,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 Y253H ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26130,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33944,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35473,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 V299L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35477,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119173,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862962G>A",
            "cDna": "c.749G>A",
            "protein": "p.G250E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}